A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

Overview

The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival allergen challenge (CAC) model. It is hypothesized that low-dose brimonidine tartrate ophthalmic solution will be more effective than vehicle in the prevention of conjunctival redness induced by conjunctival allergen challenge when instilled prior to the allergen challenge.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: March 2011

Interventions

  • Drug: Vehicle
    • one drop in each eye at designated visits
  • Drug: Brimonidine Tartrate 0.01%
    • one drop in each eye at designated visits
  • Drug: Brimonidine Tartrate 0.025%
    • one drop in each eye at designated visits
  • Drug: Oxymetazoline HCl 0.025%
    • one drop in each eye at designated visits

Arms, Groups and Cohorts

  • Other: Vehicle
  • Active Comparator: Brimonidine Tartrate 0.01%
  • Active Comparator: Oxymetazoline HCl 0.025%
  • Active Comparator: Brimonidine Tartrate 0.025%

Clinical Trial Outcome Measures

Primary Measures

  • Conjunctival Redness
    • Time Frame: at specified timepoints for up to 30 minutes

Participating in This Clinical Trial

Inclusion Criteria

  • Be at least 18 years of age; – If female, cannot be not pregnant or nursing – Have a positive skin test reaction to cat hair, cat dander, grasses, ragweed, dog dander, cockroach, dust mite, and/or trees within the past 24 months; – Have a calculated best corrected visual acuity of 0.6 logMAR or better in each eye as measured using an ETDRS chart; Exclusion Criteria:

  • Have known contraindications or sensitivities to the use of any of the study medications(s) or their components; – Have any ocular condition that, in the opinion of the investigator, could affect the subject's safety; – Have a presence of active ocular infection; – Use specified disallowed medications during the study or appropriate pre-study washout period; – Have any significant illness; – Have planned surgery (ocular or systemic) during the trial period or within 30 days after; – Have used an investigational drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device study within 30 days of the study; – Be a female who is currently pregnant or nursing.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Eye Therapies, LLC
  • Collaborator
    • ORA, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.